« Back
Home /
Talazoparib

Talazoparib

Item no.	HY-16106-50mg
Manufacturer	MedChem Express
CASRN	1207456-01-6
Amount	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 200 mg 50 mg 5 mg
Category	Oncology Metabolism Diabetes Inhibitors & Compound Libraries Small Molecules By Organ Breast Cancer
Type	Inhibitors
Specific against	other
Purity	99.89
Citations	[1]Wang B, et al. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent. J Med Chem. 2016 Jan 14;59(1):335-57.\|[2]Shen Y, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.Clin Cancer Res. 2013 Sep 15;19(18):5003-15. ACS Appl Mater Interfaces. 2019 Apr 3;11(13):12342-12356. \|Adv Sci (Weinh). 2024 Jul 8:e2400140.\|Adv Sci (Weinh). 2024 Mar 14:e2307940.\|Am J Cancer Res. 2020 Aug 1;10(8):2649-2676.\|Am J Cancer Res. 2024 Jan 15;14(1):378-389.\|Biochem Pharmacol. 2025 Feb 28:116843.\|Bioeng Transl Med. 2019 Jun 14;4(2):e10131. \|Bioinformatics. 2022 Jul 26;btac533.\|Biomed Res Int. 2023 Feb 6.\|bioRxiv. 2023 Apr 17.\|bioRxiv. 2023 Jun 22.\|bioRxiv. 2023 Jun 28.\|bioRxiv. 2024 Jul 10:2024.07.09.602803.\|bioRxiv. 2024 Nov 26:2024.11.21.624591.\|bioRxiv. April 22, 2021.\|BMC Cancer. 2022 Mar 23;22(1):312.\|Br J Cancer. 2024 May 28.\|Cancer Cell Int. 2023 Jun 27;23(1):128.\|Cancer Cell. 2020 Dec 14;38(6):844-856.e7.\|Cancer Discov. 2017 Sep;7(9):984-998.\|Cancer Discov. 2022 May 12;candisc.1181.2021.\|Cancer Lett. 2021 Jan 22;S0304-3835(21)00024-0.\|Cancer Lett. 2021 Mar 1;500:208-219.\|Cancer Lett. 2022 Aug 1;215851.\|Cancer Res. 2021 Jun 14.\|Cancer Res. 2023 Sep 11.\|Cell Biosci. 2024 Feb 6;14(1):20.\|Cell Rep. 2023 Oct 16;42(10):113256.\|Cell Rep. 2024 Jul 18;43(8):114522.\|Clin Cancer Res. 2017 Feb 15;23(4):1001-1011. \|Data Brief. 22 September 2021, 107394.\|Département de Pharmacologie et Physiologie, Faculté de Médecine. 2020 Jun.\|Drug Des Devel Ther. 2020 Feb 25;14:783-793.\|EBioMedicine. 2018 Dec;38:47-56. \|EBioMedicine. 2020 Sep;59:102923.\|Front Oncol. 2021 Jul 9;11:681441.\|Genes (Basel). 2023 Jun 20, 14(6), 1295.\|Int J Cancer. 2024 Apr 15.\|Int J Mol Sci. 2022, 23(22), 14338\|Int J Mol Sci. 2020 Feb 11;21(4):1185.\|Integr Biol (Camb). 2019 Apr 1;11(4):130-141.\|Invest New Drugs. 2021 Mar 12.\|J Clin Invest. 2021 Jun 1;131(11):146256.\|J Med Chem. 2023 Aug 21.\|J Pers Med. 2023 Aug 27, 13(9), 1315.\|Methods Mol Biol. 2018;1711:351-398.\|Mol Cell. 2017 May 18;66(4):503-516.e5. \|Nat Cancer. 2022 Oct;3(10):1211-1227.\|Nat Commun. 2023 Dec 9;14(1):8161.\|Nat Commun. 2019 Jun 11;10(1):2556. \|Nat Genet. 2022 Dec;54(12):1983-1993.\|Neoplasia. 2019 Jul 27;21(9):863-871.\|NPJ Precis Oncol. 2025 Mar 12;9(1):69.\|Oncogene. 2017 Aug 17;36(33):4682-4691.\|Oncogene. 2021 Sep 10.\|Oncogenesis. 2025 Mar 1;14(1):4.\|Oncol Lett. 2025 January 7.\|Oncol Rep. 2019 Nov;42(5):2097-2107.\|Oxid Med Cell Longev. 14 Jul 2022.\|Patent. US20180263995A1.\|Patent. US20180362972A1.\|Patent. US20200078369A1\|Patent. US20200129476A1\|Patent. US20210030680A1.\|Patent. US20220054606A1.\|PLoS One. 2024 Apr 16;19(4):e0302130.\|Radiother Oncol. 2021 Jan 29;157:175-181.\|Research Square Preprint. 2024 Feb 2.\|Research Square Print. January 4th, 2023.\|Sci Adv. 2022 Feb 18;8(7):eabl9794.\|Sci Rep. 2023 Feb 27;13(1):3334.\|Theranostics. 2020 Jul 25;10(21):9477-9494. \|University of London. 2021 Sep.\|University of Pittsburgh. 2024.\|DNA Repair (Amst). 2019 Jan;73:64-70.
Smiles	O=C1NN=C2C3=C1C=C(F)C=C3N[C@H](C4=CC=C(F)C=C4)[C@H]2C5=NC=NN5C
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	BMN-673,LT-673
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	PARP
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	380.35
Product Description	Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 25 mg/mL (ultrasonic)
Manufacturer - Pathway	Cell Cycle/DNA Damage; Epigenetics
Isoform	PARP1; PARP2
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-16106-50mg-safety-datasheet.pdf